These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29156738)

  • 1. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
    Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
    Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
    Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
    J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intertumoral Heterogeneity of CD3
    Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment.
    Kawatoko S; Kohashi K; Torisu T; Sasaki T; Umekita S; Oki E; Nakamura M; Kitazono T; Oda Y
    Pathol Res Pract; 2022 Oct; 238():154124. PubMed ID: 36137397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.
    Feng YC; Ji WL; Yue N; Huang YC; Ma XM
    Cancer Manag Res; 2018; 10():105-113. PubMed ID: 29403308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
    Kim ST; Klempner SJ; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Lee J
    Oncotarget; 2017 Sep; 8(44):77415-77423. PubMed ID: 29100397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.
    Xin H; Zhou C; Wang G; Liu Y; Zhang J; Liu Y; Li B; Zhang J; Su M; Li Z; Wang G
    Heliyon; 2023 Feb; 9(2):e13048. PubMed ID: 36814622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
    Yang L; Liu S; He W; Xiong Z; Xia L
    BMC Cancer; 2023 Mar; 23(1):221. PubMed ID: 36894899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry.
    Yan H; Li Y; Wang X; Qian J; Xu M; Peng J; Huang D
    Front Oncol; 2022; 12():867658. PubMed ID: 35669431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
    Jary M; Liu WW; Yan D; Bai I; Muranyi A; Colle E; Brocheriou I; Turpin A; Radosevic-Robin N; Bourgoin P; Penault-Llorca F; Cohen R; Vernerey D; André T; Borg C; Shanmugam K; Svrcek M
    Mol Oncol; 2022 Jun; 16(11):2260-2273. PubMed ID: 34954864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair proteins expression and tumor-infiltrating T-cells in colorectal cancer.
    Shigaki T; Fujiyoshi K; Sudo T; Kawahara A; Nakane H; Yomoda T; Nagasu S; Kinugasa T; Akiba J; Fujita F; Akagi Y
    Oncol Lett; 2022 Nov; 24(5):396. PubMed ID: 36276483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
    Wang T; Wu L; Wang S; Shi X; Liu H; Deng W
    Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
    Ashizawa M; Okayama H; Ishigame T; Thar Min AK; Saito K; Ujiie D; Murakami Y; Kikuchi T; Nakayama Y; Noda M; Tada T; Endo H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2019 Jun; 17(6):1403-1413. PubMed ID: 30872332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.